StreetInsider.com News Articles

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life sciences Group dedicated to integrated oncology diagnostics, today announces the signing of two new distribution agreements in Romania and Saudi Arabia, respectively with Proton Impex 2000 S.R.L. and H-Care Medical Est., further strengthening the Group’s international commercial network in pathology and cancer

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific Signs New Distribution Agreements in Romania and Saudi Arabia, Strengthening Its International Commercial Network

Wed, 05 Aug 2026 12:00:00 -0400

€1.92 million in Romania and €2.05 million in Saudi Arabia in five-year minimum contractual purchase commitments
Agreements covering Aliko Scientific’s liquid-based cytology, FISH, microscopy and imaging solutions
Partnerships supporting local market access, regulatory deployment and commercialization in two high-potential oncology diagnostics markets

PARIS--(BUSINESS WIRE)-- Regulatory News:

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Ikonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments

Thu, 30 Jul 2026 15:49:00 -0400

Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex’ full-year contribution and the progressive rollout of Aliko Scientific’s offering
EBITDA improved by 32.9% to a loss of €1.14 million (vs. a loss of €1.70 million in 2024), alongside a 7.6% reduction in operating expenses excluding depreciation and amortization
Continued industrial and commercial rollout of the integrated oncology diagnostics platform, notably through the US patent for ACTA, the launch of Urine24 and the exclusive distribution agreement with Menarini Diagnostics

PARIS--(BUSINESS WIRE)-- Regulatory News:

ALIKO Scientific (Ikonisys SA – Euronext Growth Paris: ALIKO), an international life

Hospitex signs deal for Uzbek cancer screening feasibility study

Thu, 23 Jul 2026 01:30:23 -0400

Aliko Scientific SA (Euronext Growth Paris: ALIKO), through its Italian subsidiary Hospitex International S.r.l., has signed an agreement with the Jizzakh branch of the Republican Scientific and Practical Centre specializing in oncology and radiology in Uzbekistan to conduct a feasibility study for a potential national urinary tract cancer screening program.

The study will assess the technical, operational, regulatory, financial, and organizational conditions required to potentially launch a pilot screening program based on Hospitex's Urine24 model. Work under the agreement has already begun.

The scope of the feasibility study includes operational workflow definition, laboratory and logistics assessment, legal and regulatory review, financial modeling,

Hospitex signs deal for Uzbek cancer screening feasibility study

Thu, 23 Jul 2026 01:30:23 -0400

The scope of the feasibility study includes operational workflow definition, laboratory and logistics assessment, legal and regulatory review, financial modeling,

Hospitex signs deal for Uzbek cancer screening feasibility study

Thu, 23 Jul 2026 01:30:23 -0400

The scope of the feasibility study includes operational workflow definition, laboratory and logistics assessment, legal and regulatory review, financial modeling,

Hospitex signs deal for Uzbek cancer screening feasibility study

Thu, 23 Jul 2026 01:30:23 -0400

The scope of the feasibility study includes operational workflow definition, laboratory and logistics assessment, legal and regulatory review, financial modeling,

Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project

Thu, 23 Jul 2026 01:30:00 -0400

Confirmation of the growing international interest in Urine24 and significant recognition of Aliko Scientific’s expertise in large-scale oncological diagnostic solutions
Immediate launch of a comprehensive feasibility study covering the technical, operational, regulatory, financial and organizational aspects of the future programme
An initial phase of potential implementation estimated at approximately €1 million, subject to positive conclusions from the study and the completion of the required procedures

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific SA (former Ikonisys SA - Euronext Growth Paris: ALIKO) – today announced that its wholly-owned Italian subsidiary, Hospitex International S.r.l., has signed a first agreement with the Jizzakh branch

Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project

Thu, 23 Jul 2026 01:30:00 -0400

Confirmation of the growing international interest in Urine24 and significant recognition of Aliko Scientific’s expertise in large-scale oncological diagnostic solutions
Immediate launch of a comprehensive feasibility study covering the technical, operational, regulatory, financial and organizational aspects of the future programme
An initial phase of potential implementation estimated at approximately €1 million, subject to positive conclusions from the study and the completion of the required procedures

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project

Thu, 23 Jul 2026 01:30:00 -0400

Confirmation of the growing international interest in Urine24 and significant recognition of Aliko Scientific’s expertise in large-scale oncological diagnostic solutions
Immediate launch of a comprehensive feasibility study covering the technical, operational, regulatory, financial and organizational aspects of the future programme
An initial phase of potential implementation estimated at approximately €1 million, subject to positive conclusions from the study and the completion of the required procedures

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project

Thu, 23 Jul 2026 01:30:00 -0400

Confirmation of the growing international interest in Urine24 and significant recognition of Aliko Scientific’s expertise in large-scale oncological diagnostic solutions
Immediate launch of a comprehensive feasibility study covering the technical, operational, regulatory, financial and organizational aspects of the future programme
An initial phase of potential implementation estimated at approximately €1 million, subject to positive conclusions from the study and the completion of the required procedures

PARIS--(BUSINESS WIRE)-- Regulatory News:

Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project

Thu, 23 Jul 2026 01:30:00 -0400

Confirmation of the growing international interest in Urine24 and significant recognition of Aliko Scientific’s expertise in large-scale oncological diagnostic solutions
Immediate launch of a comprehensive feasibility study covering the technical, operational, regulatory, financial and organizational aspects of the future programme
An initial phase of potential implementation estimated at approximately €1 million, subject to positive conclusions from the study and the completion of the required procedures

PARIS--(BUSINESS WIRE)-- Regulatory News: